Source:http://linkedlifedata.com/resource/pubmed/id/17138816
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2007-3-7
|
pubmed:abstractText |
Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:Chanan-KhanAsher AAA,
pubmed-author:KaufmanJonathan LJL,
pubmed-author:LonialSagarS,
pubmed-author:MehtaJayeshJ,
pubmed-author:MillerKena CKC,
pubmed-author:MunshiNikhil CNC,
pubmed-author:RichardsonPaul GPG,
pubmed-author:SchlossmanRobertR,
pubmed-author:SinghalSeemaS,
pubmed-author:TarimanJosephJ
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
109
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2604-6
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:17138816-Adult,
pubmed-meshheading:17138816-Aged,
pubmed-meshheading:17138816-Aged, 80 and over,
pubmed-meshheading:17138816-Boronic Acids,
pubmed-meshheading:17138816-Female,
pubmed-meshheading:17138816-Humans,
pubmed-meshheading:17138816-Male,
pubmed-meshheading:17138816-Middle Aged,
pubmed-meshheading:17138816-Multicenter Studies as Topic,
pubmed-meshheading:17138816-Multiple Myeloma,
pubmed-meshheading:17138816-Pyrazines,
pubmed-meshheading:17138816-Renal Insufficiency,
pubmed-meshheading:17138816-Retrospective Studies
|
pubmed:year |
2007
|
pubmed:articleTitle |
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
|
pubmed:affiliation |
Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
|
pubmed:publicationType |
Journal Article
|